Will NICE guidelines on the management of type 2 diabetes improve diabetes care?

Practical Diabetes International

Volumn 21, Issue 1, 2004, Pages 3-6

  Winocour, Peter H ^a   Shaw, Ken ^b   Greenwood, Richard ^c  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LISINOPRIL; METFORMIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG EFFICACY; EARLY DIAGNOSIS; HEALTH CARE ORGANIZATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY FUNCTION TEST; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRACTICE GUIDELINE; SCREENING TEST;

EID: 1342304420     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.563     Document Type: Article

References (18)

1. National Institute for Clinical Excellence. Inherited Clinical Guideline E. Management of type 2 diabetes: Retinopathy - screening and early management. London: National Institute for Clinical Excellence, 2002.
2. National Institute for Clinical Excellence. Inherited Clinical Guideline F. Management of type 2 diabetes: Renal disease - prevention and early management. London: National Institute for Clinical Excellence, 2002.
3. National Institute for Clinical Excellence. Inherited Clinical Guideline G. Management of type 2 diabetes: Management of blood glucose. London: National Institute for Clinical Excellence, 2002.
4. National Institute for Clinical Excellence. Inherited Clinical Guideline H. Management of type 2 diabetes: Management of blood pressure and blood lipids. London: National Institute for Clinical Excellence, 2002.
5. Henricsson M, Nilsson A, Janzon L, et al. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin dependent diabetes mellitus. Diabetic Med 1997; 14: 123-131.
6. UKPDS 3. The prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes. Hypertension 1985; 7(Suppl II): 8-13.
7. Winocour PH, Ainsworth A, Williams R. The Association of British Clinical Diabetologists (ABCD) Survey of Secondary Care Services for Diabetes in the United Kingdom 2000. 1: Methods and major findings. Diabetic Med 2002; 19: 327-333.
8. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. Antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975.
9. Thomas A. Glycated haemoglobin - quality assurance: the UK experience. In: Monitoring glycaemic control in the diabetic patient, John WG (ed). London: Harcourt Health Communications, 2001; 103-122.
10. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (Suppl 2): S1-S29.
11. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002; 324: 1577-1580.
12. National Institute for Clinical Excellence. Technology Appraisal 63. Guidance on the use of glitazones for the treatment of type 2 diabetes. London: National Institute for Clinical Excellence, 2003.
13. Winocour PH, Fisher BM. Prediction of cardiovascular risk in people with diabetes. Diabetic Med 2003; 20: 515-527.
14. Heart Protection Study Collaborative Group. MIRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
15. Hansson L, Zanchetti A, Carruthers SG, et al for the HOT study group. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
16. Damsgaard EM, Mogensen CE. Microalbuminuria in elderly hyperglycaemic patients and controls Diabetic Med 1986; 3: 430-435.
17. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
18. Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.